Browsing by Author "Terek, MC"

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Evaluation Of VEGF, EGF-R AND TGF-α In Placenta Of Pregnancies With Preeclampsia By Immunohistochemistry
    Çirpanli, T; Akercan, F; Terek, MC; Özcakir, HT; Giray, G; Sagol, S; Karadadas, N
    Objective: The aim of the study is to determine VEGF, EGFR and TGF-alpha with the immunohistochemical staining in placenta biopsies of patients with preeclampsia. Design: Prospective case control study. Materials and Methods: Biopsies from the placenta were obtained from ten patients with preeclapmsia and ten patients of control group during the cesarean section. Placenta biopsies were examined for VEGF, EGF-R and TGF-alpha distribution with avidin-biotinperoxidase immunohistochemistry. The staining intensities were graded semi-quantitatively by the two histologists who were blinded to the groups and the H-score was calculated by light microscopic examination. Results: The VEGF, EGFR and TGF-alpha expression was significantly higher in placenta biopsies of preeclamptic patient compared to controls (271.2 +/- 22.65 versus 201.9 +/- 12.33, p=0.000; 186.3 +/- 4.98 versus 150.3 +/- 5.7, p=0.000; 185.1 +/- 7.48 versus 169.2 +/- 6.19, p=0.000; respectively). Conclusion: Immunostaining of VEGF, EGF-R and TGF-alpha is significantly higher in placenta biopsies in patients with preeclampsia.
  • No Thumbnail Available
    Item
    Evaluation of VEGF in placental bed biopsies from preeclamptic women by immunohistochemistry
    Cirpan, T; Akercan, F; Terek, MC; Kazandi, M; Ozcakir, HT; Giray, G; Sagol, S
    Objective: The aim of the study was to determine VEGF protein with immunohistochemical staining in placental bed biopsies of preeclamptic pregnancies in comparison to normal controls. Design: Prospective cohort Study. Methods: The placental bed biopsies were obtained from 12 patients with preeclapmsia and ten patients for a control group at the time of cesarean delivery. Tissue samples of the placental bed were examined for VEGF protein distribution with avidin-biotin-peroxidase immunohistochemistry. Two blinded histopathologists were asked to score each sample for the intensity of staining and the number of cells stained in a randomly selected HPF of each sample. The resulting H-score was computed as a product of intensity and percent of cells stained. Results: VEGF expression was significantly lower in both the myometrium and stroma of the preeclamptic group compared to the control group (77.2 +/- 25.4 vs 134 +/- 44.3, p = 0.007; 194.1 +/- 20.7 vs 170.2 +/- 17, p = 0.017, respectively). Conclusion: VEGF expression is significantly lower in placental bed biopsies of preeclamptic pregnancies.
  • No Thumbnail Available
    Item
    The immunohistochemical evaluation of VEGF in placenta biopsies of pregnancies complicated by preeclampsia
    Akercan, F; Cirpan, T; Terek, MC; Ozcakir, HT; Giray, G; Sagol, S; Karadadas, N
    Objective The study was designed to determine the protein levels of vascular endothelial growth factor (VEGF) in the placenta biopsies of patients with preeclampsia and compare with normal controls. Design Prospective cohort study. Methods The placental biopsies were obtained from ten patients with preeclampsia and ten patients of control group at the time of delivery. Avidin-biotin-peroxidase immunohistochemistry was then performed to identify levels of VEGF protein within the tissue and a semi-quantitative method was devised to score the amount of staining present in the sample. Two histopathologists who were blinded to the groups were asked to score each sample for the intensity of staining and the number of cells stained in a randomly selected per high-power fields of each sample. The resulting H-score was computed as a product of intensity and percent of cells stained. Results The VEGF expression was significantly higher in placenta biopsies of preeclamptic patients compared to that of controls (271.2 +/- 22.65 vs. 201.9 +/- 12.33, P = 0.000). Conclusion Immunostaining of VEGF is significantly higher in placenta biopsies of patients with preeclampsia.
  • No Thumbnail Available
    Item
    Effects of leptin on the viability of human ovarian cancer cells and changes in cytokine expression levels
    Dincer, F; Atmaca, H; Akman, L; Oktay, LM; Karaca, B; Terek, MC
    Background: Obesity is associated with increased mortality among ovarian cancer and is a poor prognostic factor. There are significant links between the leptin hormone, a product of the obesity gene, and the development of ovarian cancer. Leptin is a vital hormone-like cytokine secreted from adipose tissue and is mainly involved in the maintenance of energy homeostasis. It regulates several intracellular signaling pathways and also interacts with various hormones and energy regulators. It acts as a growth factor by stimulating cell proliferation and differentiation and in this way contributes to cancer cell development. The aim of the study was to investigate the effects of leptin on human ovarian cancer cells. Methods: In this study, the effects of increasing the concentration of leptin were investigated on the cell viability of OVCAR-3 and MDAH-2774 ovarian cancer lines by MTT assay. Moreover, to elucidate the molecular mechanisms of leptin in ovarian cancer cells, changes in the expression levels of 80 cytokines were evaluated after leptin treatment via a human cytokine antibody array. Results: Leptin increases the proliferation of both ovarian cancer cell lines. IL-1 level was increased in OVCAR-3 cells and TGF-beta level was increased in MDAH-2774 cells after leptin treatment. A decrease in IL-2, MCP-2/CCL8 and MCP-3/CCL7 levels was detected in both ovarian cancer cell lines with leptin administration. An increase in IL-3 and IL-10 expressions, insulin-like growth factor binding proteins (IGFBP) IGFBP-1, IGFBP-2 and IGFBP-3 levels were detected in both ovarian cancer cell lines with leptin administration. In conclusion; leptin has a proliferative effect on human ovarian cancer cell lines and affects different cytokines in different types of ovarian cancer cells.
  • No Thumbnail Available
    Item
    Effect of surgical staging on 539 patients with borderline ovarian tumors: A Turkish Gynecologic Oncology Group study
    Guvenal, T; Dursun, P; Hasdemir, PS; Hanhan, M; Guven, S; Yetimalar, H; Goksedef, BP; Sakarya, DK; Doruk, A; Terek, MC; Saatli, B; Guzin, K; Corakci, A; Deger, E; Celik, H; Cetin, A; Ozsaran, A; Ozbakkaloglu, A; Kolusari, A; Celik, C; Keles, R; Sagir, FG; Dilek, S; Uslu, T; Dikmen, Y; Altundag, O; Ayhan, A
    Objective. The objectives of this study were to examine demographic and clinicopathologic characteristics and to determine the effects of primary surgery, surgical staging and the extensiveness of staging. Methods. In a retrospective Turkish multicenter study, 539 patients, from 14 institutions, with borderline ovarian tumors were investigated. Some of the demographic, clinical and surgical characteristics of the cases were evaluated. The effects of type of surgery, surgical staging; complete or incomplete staging on survival rates were calculated by using Kaplan-Meier method. Results. The median age at diagnosis was 40 years (range 15-84) and 71.1% of patients were premenopausal. The most common histologic types were serous and mucinous. Majority of the staged cases were in Stage IA (735%). 242 patients underwent conservative surgery. Recurrence rates were significantly higher in conservative surgery group (8.3% vs. 3%). Of all patients in this study, 294 (545%) have undergone surgical staging procedures. Of the patients who underwent surgical staging, 228 (77.6%) had comprehensive staging including lymphadenectomy. Appendectomy was performed on 204 (37.8%) of the patients. The median follow-up time was 36 months (range 1-120 months). Five-year survival rate was 100% and median survival time was 120 months. Surgical staging, lymph node sampling or dissection and appendectomy didn't cause any difference on survival. Conclusion. Comprehensive surgical staging, lymph node sampling or dissection and appendectomy are not beneficial in borderline ovarian tumors surgical management. (C) 2013 Elsevier Inc. All rights reserved.
  • No Thumbnail Available
    Item
    Multicenter Analysis of Gestational Trophoblastic Neoplasia in Turkey
    Ozalp, SS; Telli, E; Oge, T; Tulunay, G; Boran, N; Turan, T; Yenen, M; Kurdoglu, Z; Ozler, A; Yuce, K; Ulker, V; Arvas, M; Demirkiran, F; Bese, T; Tokgozoglu, N; Onan, A; Sanci, M; Gokcu, M; Tosun, G; Dikmen, Y; Ozsaran, A; Terek, MC; Akman, L; Yetimalar, H; Kilic, DS; Gungor, T; Ozgu, E; Yildiz, Y; Kokcu, A; Kefeli, M; Kuruoglu, S; Yuksel, H; Guvenal, T; Hasdemir, PS; Ozcelik, B; Serin, S; Dolanbay, M; Arioz, DT; Tuncer, N; Bozkaya, H; Guven, S; Kulaksiz, D; Varol, F; Yanik, A; Ogurlu, G; Simsek, T; Toptas, T; Dogan, S; Camuzoglu, H; Api, M; Guzin, K; Caliskan, E; Doger, E; Cakmak, B; Ilhan, TT
    Background: To evaluate the incidence, diagnosis and management of GTN among 28 centers in Turkey. Materials and Methods: A retrospective study was designed to include GTN patients attending 28 centers in the 10-year period between January 2003 and May 2013. Demographical characteristics of the patients, histopathological diagnosis, the International Federation of Gynecology and Obstetrics (FIGO) anatomical and prognostic scores, use of single-agent and multi-agent chemotherapy, surgical interventions and prognosis were evaluated. Results: From 2003-2013, there were 1,173,235 deliveries and 456 GTN cases at the 28 centers. The incidence was calculated to be 0.38 per 1,000 deliveries. According to the evaluated data of 364 patients, the median age at diagnosis was 31 years (range, 15-59 years). A histopathological diagnosis was present for 45.1% of the patients, and invasive mole, choriocarcinoma and PSTTs were diagnosed in 22.3% (n=81), 18.1% (n=66) and 4.7% (n=17) of the patients, respectively. Regarding final prognosis, 352 (96.7%) of the patients had remission, and 7 (1.9%) had persistence, whereas the disease was mortal for 5 (1.4%) of the patients. Conclusions: Because of the differences between countries, it is important to provide national registration systems and special clinics for the accurate diagnosis and treatment of GTN.